Decoy Therapeutics Inc. (DCOY)
DCOY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1615219/000161521923000030/0001615219-23-000030-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | DCOY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001615219 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2022
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$31.6M |
| Operating income | -$31.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $12.1M |
| Total assets | $14.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $8.2M cash; operating cash flow -$2.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 2,385,282 (2026-11-11); 5,862,178 a year earlier; 3,938,433 three years earlier. 1y figure adjusted for splits (1-for-12 overall); 3y figure adjusted for splits (1-for-1440 overall). | Cover page 2026-11-11 |
| Reverse splits, 3 years | 3; latest 1-for-12 on 2026-03-09 | Source 2026-03-09 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-13 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-02 |
| Auditor | Ernst & Young LLP, Houston, Texas, United States | PCAOB Form AP 2026-04-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $20K, sold $17 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $307K | -$3.0M | -$2.6M | $8.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $228K | -$2.4M | -$2.7M | $8.3M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$2.2M | -$2.9M | $7.8M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$9.0M | -$1.1M | $10.7M | $0 | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $0 | -$873K | -$1.6M | $4.8M | $0 | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $0 | -$958K | -$862K | $795K | $0 | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$1.7M | -$1.2M | $1.8M | $112K | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$1.5M | -$743K | $2.4M | $222K | Needs four quarters | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-13 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-09-23 |
| Latest proxy | DEF 14A | 2026-08-04 |
Source: SEC EDGAR submissions feed, 746 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.7% |
| 1 month | -21.4% |
| 3 months | -72.4% |
| Year to date | -87.5% |
| 1 year | -93.3% |
| From 52-week high | -93.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SBFM | Sunshine Biopharma Inc. | $2.60 | -3.70% | $2.1M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
| JUNS | Jupiter Neurosciences Inc. | $1.70 | -8.11% | $2.2M |
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| PRFX | PRF Technologies Ltd. | $0.6948 | -11.22% | $2.4M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
| GNPX | Genprex Inc. | $1.90 | -8.65% | $2.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier